Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 6;30(2):oyae228.
doi: 10.1093/oncolo/oyae228.

Proceedings of the 1st biannual bridging the gaps in lung cancer conference

Narjust Florez  1 , Sandip P Patel  2 , Heather Wakelee  3 , Lyudmila Bazhenova  4 , Erminia Massarelli  5 , Ravi Salgia  5 , Brendon Stiles  6 , Solange Peters  7 , Jyoti Malhotra  8 , Shirish M Gadgeel  9 , Jorge J Nieva  10 , Michelle Afkhami  11 , Fred R Hirsch  12 , Matthew Gubens  13 , Tina Cascone  14 , Benjamin Levy  15 , Joshua Sabari  16 , Hatim Husain  17 , Patrick C Ma  18 , Leah M Backhus  19 , Puneeth Iyengar  20 , Percy Lee  21 , Russell Miller  17 , Jacob Sands  1 , Edward Kim  5
Affiliations

Proceedings of the 1st biannual bridging the gaps in lung cancer conference

Narjust Florez et al. Oncologist. .

Abstract

Lung cancer is the leading cause of cancer death in the US and globally. The mortality from lung cancer has been declining, due to a reduction in incidence and advances in treatment. Although recent success in developing targeted and immunotherapies for lung cancer has benefitted patients, it has also expanded the complexity of potential treatment options for health care providers. To aid in reducing such complexity, experts in oncology convened a conference (Bridging the Gaps in Lung Cancer) to identify current knowledge gaps and controversies in the diagnosis, treatment, and outcomes of various lung cancer scenarios, as described here. Such scenarios relate to biomarkers and testing in lung cancer, small cell lung cancer, EGFR mutations and targeted therapy in non-small cell lung cancer (NSCLC), early-stage NSCLC, KRAS/BRAF/MET and other genomic alterations in NSCLC, and immunotherapy in advanced NSCLC.

Keywords: clinical decision-making; controversies; lung cancer diagnosis; lung cancer management; lung cancer treatment; unanswered questions.

PubMed Disclaimer

Conflict of interest statement

S.P.P. reports scientific advisory income from: Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Certis, Eli Lilly, Jazz, Genentech, Illumina, Merck, Pfizer, Signatera, Tempus; research funding (inst.) from Amgen, AstraZeneca/MedImmune, A2bio, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech. H.W. receives research funding (inst) from AstraZeneca /Medimmune; Bayer; BMS; Genentech/Roche; Helsinn; Merck; SeaGen; Xcovery; reports advisory board participation for IOBiotech, Mirati, OncoC4, Beigene; and serves as an unpaid consultant to BMS, Genentech/Roche; Merck; AstraZeneca. L.B. reports consulting/advisory role with Novocure, Neuvogen, Abbvie, Genentech, Janssen, Regeneron, Merck, Gielad, Anheart, Summit, Bioatla, Bayer, Boehringer Ingleheim, Pfizer, Teligene, Sanofi. E.M. serves on the scientific advisory board for Janssen, Sanofi, BMS, Daiichi, Abbvie, Mirati, Fusion Pharmaceutical, Gilead; reports speaker bureau honoraria from AstraZeneca, Lilly, Takeda, Alliace (Daiichi Sankyo + AstraZeneca), Mirati; and receives steering committee honoraria from Daiichi Sankyo + AstraZeneca. B.S. reports a consulting/advisory role with Pfizer, AstraZeneca, Merck, BMS, Regeneron, Medtronic, Roche/Genentech, Galvanize Therapeutics; receives research funding from: BMS, BMS Foundation, American Cancer Society; and serves on the scientific advisory board of: Lung Cancer Research Foundation, LUNGevity S.P. reports a consulting/advisory role with AbbVie, Amgen, Arcus, AstraZeneca, Bayer, Beigene, BioNTech, BerGenBio, Bicycle Therapeutics, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F-Star, Foundation Medicine, Genmab, Genzyme, Gilead, GSK, Hutchmed, Illumina, Incyte, Ipsen, iTeos, Janssen, Qlucore, Merck Sharp and Dohme, Merck Serono, Merrimack, Mirati, Nuvation Bio, Nykode Therapeutics, Novartis, Novocure, Pharma Mar, Promontory Therapeutics, Pfizer, Regeneron, Roche/Genentech, Sanofi, Seattle Genetics, Takeda, Zymeworks; Talk in a company’s organized public event: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Foundation Medicine, GSK, Illumina, Ipsen, Merck Sharp and Dohme, Mirati, Novartis, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, Takeda; served as Principal investigator in trials (with institutional financial support for clinical trials) sponsored by Amgen, Arcus, AstraZeneca, Beigene, Bristol-Myers Squibb, Eli Lilly, GSK, iTeos, Merck Sharp and Dohme, Mirati, Pharma Mar, Promontory Therapeutics, Roche/Genentech, Seattle Genetics. S.M.G. reports consulting advisory role with Astra-Zeneca, Mirati, Genentech/Roche, Pfizer, Boehringer-Ingelheim, Arcus, Abbvie, Gilead, Blueprint, Bayer, Regeneron. J.J.N. reports a consulting role with: Aadi Biosciences, ANP Technologies, Astra Zeneca, BioAtla, G1 Therapeutics, Genentech, Mindmed, Naveris, Sanofi; serves on the Advisory Board of: Kalivir; receives research support from: Genentech, Merck; reports intellectual property with: Cansera; and has ownership Interests in: Cansera, Epic Sciences, Indee Bio, Amgen, Johnson & Johnson, Novartis. F.R.H. serves on scientific advisory boards for: Amgen, AstraZeneca/Daiichi, Regeneron, Sanofi, Novartis, Merus, Oncohost, Novocure, Nectin Therapeutics, G1 Therapeutics. M.G. reports consulting/advisory role with: AnHeart, AstraZeneca, Atreca, BMS, Cardinal Health, Gilead, Invitae, Johnson and Johnson, Merus, OncoHost, Summit; received research funding (inst) from: Amgen, Johnson and Johnson, Merck, Trizell DSMC: Samsung Bioepis. T.C. reports speaker fees/honoraria from ASCO Post, AstraZeneca, Bio Ascend LLC, Bristol Myers Squibb, Clinical Care Options, IDEOlogy Health, Mark Foundation for Cancer Research, Medical Educator Consortium INC, Medscape, OncLive, PEAK Medical, PeerView, Physicians’ Education Resource, Society for Immunotherapy of Cancer, Targeted Oncology; reports advisory role/consulting fees from Arrowhead Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Genentech, Merck, ONKo-innate, Pfizer, RAPT Therapeutics, Regeneron; receives research funding (inst) from AstraZeneca, and Bristol Myers Squibb. B.L. reports consulting with. Jansenn, Daiichi Sankyo,. AstraZeneca,. Pfizer, Merck,. Eli Lilly, Genentech, Takeda, Guardant 360, BMS,. Norvatis,. Novocure. P.C.M. reports honoraria from: AstraZeneca, BeiGene. L.M.B. serves on advisory panels for: Genentech/Roche, Bristol Myers Squibb, AstraZeneca; Ethicon. P.L. reports consulting/advisory role with Varian, ViewRay, AstraZeneca, Genentech, Johnson & Johnson, Roche, RTOG foundation; honoraria from: Varian, ViewRay, AstraZeneca; Advisory: Genentech, ViewRay, AstraZeneca, Roche. R.M. reports consulting/advisory with-Olympus America.

E.M. consults for AbbVie, Sanofi, and Gilead. H.W. receives research funding from Bayer, Arrys Therapeutics, AstraZeneca/MedImmune, Bristol-Myers Squibb, Genentech/Roch, Merck, Helsinn, SeaGen and Xcovery and serves as an advisor to Mirati, IOBiotech, Merck, Genentech/Roche, Bristol-Myers Squibb and AstraZeneca. R.M. consults for Olympus Corporation. F.R.H. consults for AstraZeneca, Diichi Sankyo, Regeneron, Genzyme, Novartis, Novocure, NextCure, GI-Therapeutics, Amgen, Roche/Genentech and serves on the scientific board for Oncohost. P.C.M. received honoraria from AstraZeneca and BeiGene. The other authors report no financial relationships.

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. 10.3322/caac.21660 - DOI - PubMed
    1. Singal G, Miller PG, Agarwala V, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a Clinicogenomic Database. JAMA. 2019;321(14):1391-1399. 10.1001/jama.2019.3241 - DOI - PMC - PubMed
    1. Society AC. Cancer facts & figures 2023. Atlanta; 2023.
    1. Howlader NNA, Krapcho M, Miller D, et al. Cronin KA SEER cancer statistics review, 1975-2016. National Cancer Institute, 2018. Accessed March 1, 2024. https://seer.cancer.gov/csr/1975_2016/
    1. Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640-649. 10.1056/NEJMoa1916623 - DOI - PMC - PubMed

Publication types